Key Takeaways for Dental Practice Owners
- Information asymmetry between one-time sellers and frequent DSO buyers can create a serious disadvantage that may cost dentists millions without professional representation.
- A structured, auction-style bid process with multiple vetted buyers often generates around 10 offers and can produce roughly 30% higher valuations than selling independently.
- Comprehensive CPA-led EBITDA analysis with clearly documented add-backs can help prevent valuation “re-trades” during due diligence and protect agreed-upon deal terms.
- Typical DSO deal structures include 60–80% cash at close, with the remainder in rollover equity and earnouts, so careful negotiation can be a key factor in maximizing after-tax outcomes.
- McLerran & Associates provides exclusive sell-side representation and has guided approximately 2,000 successful dental practice sales totaling $2 billion; schedule a free, confidential discovery call to understand your practice’s potential value.
7-Step Sale Process for Selling to Private Equity
McLerran & Associates runs a full-process engagement, not a one-off transaction. Every DSO or private equity sale follows a structured sequence designed to support value and protect the seller at each stage.
- CPA-led EBITDA analysis and practice valuation. EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is a standard measure of operating profitability. McLerran calculates EBITDA from the ground up and unpacks every discretionary, personal, and non-recurring expense to arrive at true, defensible profitability. This diligence-grade work is completed before the practice goes to market so the numbers can stand up when buyers review them.
- Side-by-side valuation across both paths. For owners who can pursue either a doctor-to-doctor sale or a DSO affiliation, McLerran quantifies the practice’s worth in both markets at the same time. That approach helps owners decide with data instead of guesswork.
- Multi-year financial forecasting and cash-flow modeling. McLerran models what each path can net the owner over 3-, 5-, 7-, and 10-year horizons. The models show how cash, equity, and earnouts behave under different scenarios and how proceeds are taxed, so owners compare real after-tax outcomes instead of headline numbers.
- Buyer vetting and marketing. The team builds a marketing deck and virtual data room. Buyers are pre-screened, and DSOs known for poor post-close environments are removed from consideration before they reach the table.
- Auction-style competitive bid process. A structured 45–60 day process solicits offers from a vetted pool of strategic and financial buyers. This process typically generates around 10 offers per listing.
- LOI negotiation and deal structuring. McLerran negotiates the Letter of Intent (LOI), which is the formal document outlining deal terms before a final contract. The LOI covers valuation, cash at close, equity structure, and earnout terms.
- Quality-of-earnings defense and closing. After the LOI, McLerran manages due diligence through closing. The team defends the agreed EBITDA when the buyer’s team scrutinizes the numbers and works to prevent the deal from being re-traded.
Comparing Paths: Private Buyer Sale vs. DSO Affiliation
McLerran & Associates runs both transition pathways in roughly equal measure: doctor-to-doctor sales and DSO or private equity affiliations. That experience gives owners a genuine side-by-side comparison that single-lane brokers often cannot provide.
The two paths can produce meaningfully different financial profiles over time. The table below illustrates how cash availability and total returns can diverge at key points: at closing, when earnouts typically conclude, and when equity recap opportunities often arise. These timing differences can be some of the main factors in deciding which path fits your goals. The table then shows conservative, illustrative cash-flow outcomes across both paths for a hypothetical premier general dental practice. All figures are illustrative ranges based on deal-structure data from multiple sources and are not guarantees of any specific outcome. Consult your own financial and tax advisors before making any decision.
| Horizon | Private Buyer (full cash at close, brief transition) | DSO Path — Conservative (60–75% cash at close, 15–30% rollover equity, 5–15% earnout; one recap assumed in years 5–7) |
|---|---|---|
| At close (Year 0) | 100% of agreed value in cash; private buyer transactions are more likely to pay the seller in full at closing | 60–85% cash at close, with the remainder in rollover equity and earnout |
| Year 3 | Proceeds invested, with no further practice upside | Earnout period typically concludes; earnouts in DSO dental deals often represent 5–15% (or up to 10–30%) of total consideration, paid over 12–36 months |
| Year 5 | Proceeds compounding in outside investments | Rollover equity approaching a potential recap window; rollover equity is typically reinvested at the DSO’s most recent PE fundraise valuation, with a potential second liquidity event in 3–7 years |
| Year 7–10 | No additional upside from the practice | Second liquidity event (recap or platform sale) can produce 2x–5x returns on rollover equity in favorable exits, although outcomes vary widely and some holders experience write-downs or liquidity delays |
The DSO path can produce a higher total economic outcome over time when the platform performs, the equity structure is sound, and the deal is negotiated by an advisor who understands these mechanics. The private-buyer path offers more certainty: full cash at close, a clean exit, and no exposure to a DSO platform’s future performance.
Valuation Mechanics and EBITDA Add-Backs
Valuation is often where quiet damage occurs. A “free” back-of-the-napkin number set by the buyer can become the anchor that determines what the owner ultimately receives, and a weak valuation analysis can be re-traded in due diligence.
McLerran builds a comprehensive, CPA-led EBITDA analysis before the practice goes to market. Every add-back, meaning a discretionary, personal, or non-recurring expense added back to net income to reflect true operating profitability, is documented and defensible. Factors that can move multiples upward can include multi-doctor staffing that reduces key-person risk, hygiene revenue above roughly 30% of collections, strong recall rates, and low government payer concentration. Factors that can suppress multiples can include heavy owner-production concentration, Medicaid revenue above roughly 50% of collections, and leases with limited remaining term.
In 2026, EBITDA multiple ranges by practice size and type can include the following general bands, although actual multiples depend on the specific practice’s fundamentals, market, and buyer pool:
- Single-location general dentistry: approximately 5x–8x normalized EBITDA for add-on acquisitions, with the range varying by practice quality and buyer competition
- Multi-location regional add-ons ($1M–$3M EBITDA): approximately 6x–9x EBITDA for general dentistry
- Emerging platform practices ($3M–$5M EBITDA): approximately 9x–11x EBITDA
- Platform-grade practices ($5M+ EBITDA): approximately 11x or higher in select cases
- Specialty practices (oral surgery, orthodontics, pediatric, endodontics, periodontics) generally command a premium of one to several turns above comparable general dentistry practices, reflecting higher operating margins, stickier patient bases, and greater consolidation activity
These are ranges, not guarantees. Your multiple is determined by your specific numbers, market, and the competitive process McLerran runs on your behalf, which leads directly into the next stage of the process.
Create Competition with an Auction-Style Bid Process
A seller who talks to only one DSO receives one offer, with no competitive tension to push the price up and no way to know whether that buyer is a strong fit. Competition can be the mechanism that produces better prices and better terms.
Once your practice’s true EBITDA and defensible valuation are established, the next step is creating the competitive tension that turns those numbers into actual offers. McLerran runs a structured, auction-style bid process over approximately 45–60 days. The firm builds a marketing deck and a virtual data room, which is a secure, organized repository of every financial and operational document a buyer needs, and solicits offers from a vetted pool of strategic buyers and financial buyers. The process typically generates around 10 offers per listing, narrows to in-person meetings with the top one to three finalists, and can produce approximately a 30% higher valuation on average than owners achieve selling on their own.
Poorly run DSOs, including weaker buyers that emerged when capital flooded the space, are removed from the process before it begins. Owners see the real market instead of a shortlist that primarily serves a broker’s relationships.
Talk with McLerran & Associates about running a competitive process for your practice; the conversation is free and confidential.
Deal Structures: Cash, Equity Rollover, and Earnouts
DSO offers are rarely simple. Owners benefit from understanding the three main components of a typical deal structure, along with the risks in each, before signing a Letter of Intent.
Cash at close is the portion paid immediately upon closing. Cash at close in dental practice sales to DSOs typically ranges from 60–80%, with many deals around 65%, reflecting higher buyer cost of capital and a shift of more risk to sellers. In favorable situations, such as a high-quality general practice in a competitive market with low Medicaid exposure, cash at close can reach 70–75% or higher.
Rollover equity is the portion of proceeds reinvested as an ownership stake in the acquiring DSO platform. Rollover equity often represents 15–30% of total consideration in DSO deals and can create a potential second liquidity event when the platform is later sold or recapitalized, typically in 3–7 years. Equity can be held at two levels:
- Joint-venture (JV) level equity, which is ownership in the local practice entity and may generate distributions but usually has a lower ceiling on upside
- Holding-company level equity, which is ownership in the DSO’s parent entity and typically carries no distributions but can have a higher ceiling that may multiply several times over if the platform exits at a premium multiple
Much of a DSO deal’s proceeds, particularly the equity rollover, can qualify for long-term capital gains tax treatment rather than ordinary income rates. That difference can materially affect net-to-seller proceeds, so a qualified tax advisor can be helpful in evaluating your specific situation.
Earnouts are contingent payments tied to the practice hitting post-close financial targets. Earnouts in DSO dental deals often represent 5–15% (or up to 10–30%) of total consideration, paid over 12–36 months. Earnout risk sits primarily with the seller because the buyer controls operations after closing, which means the buyer can make decisions that affect whether earnout targets are met. To counter that structural disadvantage, McLerran negotiates protective terms that limit the buyer’s ability to manipulate results. Same-store EBITDA measurement helps prevent the buyer from allocating corporate overhead to suppress the practice’s performance. Pro-rata catch-up provisions help ensure that a near-miss on a target still pays most of the earnout rather than nothing. Change-of-control acceleration can protect the seller if the DSO is sold before the earnout period concludes.
The risk of partnering with an undercapitalized DSO is real. Some rollover equity holders experience write-downs or liquidity delays exceeding 5 years when platforms miss growth targets. McLerran vets buyers like investments by assessing profitability, revenue growth, management quality, and private equity backing, and then steers owners away from weak platforms before a deal is signed.
Find the Right Fit: Vetting Buyers and Post-Sale Control
The highest bidder is not always the right buyer. Post-sale life, including employment terms, clinical autonomy, staff treatment, and patient care, can be just as important as the headline number for many sellers.
Nearly every DSO transaction requires the selling dentist to sign an employment agreement and remain with the practice for a specified period, typically a minimum of 5 years. Employment terms usually include base compensation plus productivity bonuses, and non-compete agreements in dental DSO sales commonly run 2–5 years with a geographic radius of 5–15 miles. McLerran negotiates these terms on the seller’s behalf and pushes for the least restrictive covenants that the market will support.
Clinical autonomy, meaning the ability to make treatment decisions without interference, is a core concern for most selling dentists. California, for example, enacted legislation effective January 1, 2026 that prohibits private equity groups from interfering with professional dental judgment, including treatment decisions, patient referrals, scheduling, and staffing. Regulatory protections vary by state, so understanding what a specific DSO’s operating model means for day-to-day clinical life becomes part of McLerran’s buyer-vetting process.
Two anonymized examples show what a competitive process can produce. In one case, a multi-doctor practice that had outgrown the doctor-to-doctor market received 8 offers through McLerran’s process and joined a well-backed group at a valuation the owners likely could not have achieved alone. In another, a 7-location pediatric group that already had offers on the table when it engaged McLerran achieved a valuation about 20% higher than those initial offers after McLerran established true EBITDA and controlled the narrative through negotiation.
Maximize Your Outcome: Quality-of-Earnings Defense and Closing
Signing a Letter of Intent is not the finish line. Due diligence, which is the buyer’s formal financial and operational review of the practice, is often where deals are re-traded and where sellers without representation can lose value they expected to receive.
McLerran defends the agreed EBITDA throughout the diligence process. When a buyer’s quality-of-earnings team, meaning the accounting professionals hired to scrutinize the seller’s financials, challenges an add-back or attempts to recharacterize an expense, McLerran responds with the documented analysis built at the start of the engagement. The firm also reminds buyers, when necessary, that other vetted bidders are waiting, which helps preserve competitive tension even after exclusivity is granted.
The result is a transaction rate of approximately 85–90% among McLerran’s clients, compared to an industry norm closer to 35–40%. Do-it-yourself close rates can run as low as 15–20%. That gap often reflects process, preparation, and advocacy through every stage of a fragile transaction.
McLerran also coordinates the broader advisor team, including attorneys, lenders, CPAs, and other specialists. The goal is to keep every party aligned on the dental-specific dynamics of the deal and maintain momentum from LOI to close.
Ready to Understand What Your Practice Is Worth?
Owners who are considering a transition, whether now or in the future, can benefit from an early valuation. Get your practice valued by McLerran & Associates at (512) 900-7989 or visit dentaltransitions.com/contact-us for a free, no-obligation consultation. If you are not ready to sell today, McLerran can update your valuation a year later at no charge rather than push you into a deal before the time feels right.
Frequently Asked Questions
What multiple will my dental practice sell for in a private equity transaction?
There is no single answer, and any advisor who gives a fixed number before reviewing your financials is likely guessing. Multiples in 2026 vary meaningfully based on practice size, EBITDA scale, number of locations, specialty, owner-production concentration, payer mix, and the competitive process used to bring the practice to market. General dentistry practices at the single-location level tend to trade at lower multiples than multi-location groups, which in turn often trade below platform-grade practices. Specialty practices generally command a premium over comparable general dentistry practices. Your multiple is determined by your specific numbers and the competition McLerran creates around them, which is exactly what the valuation work is designed to quantify before anything goes to market.
How much cash at close is realistic in a DSO deal?
Cash at close in DSO transactions has shifted over the past several years as buyer cost of capital has risen. In 2026, a range of roughly 60–80% cash at close is common, with the remainder structured as rollover equity and earnout. Higher cash-at-close outcomes, closer to 70–75% or above, tend to be achievable for high-quality practices in competitive markets with low government payer exposure. Practices with heavier Medicaid concentration or in markets with fewer active buyers may see a lower cash component. McLerran models the full deal structure, including cash, equity, and earnout, across multiple buyers so you can compare real after-tax proceeds instead of focusing only on the headline percentage.
What happens to my staff and patients after I sell to a DSO?
Finding the right fit is a central part of McLerran’s mandate, not just securing the highest price. The firm vets buyers on their post-close operating model, including how they treat existing staff, whether they preserve clinical culture, and what infrastructure and support they actually deliver compared to what they promise. As mentioned earlier, McLerran’s buyer vetting removes poorly run DSOs from consideration before any offers are solicited, which helps ensure that every finalist can deliver on both financial terms and post-close culture. Employment agreements negotiated by McLerran address clinical autonomy, staffing decisions, and the scope of operational changes the buyer can make. The goal is a strong financial outcome and a buyer whose strategy supports the legacy, patients, and staff you leave behind.
Should I sell to a private buyer or a DSO?
The right path depends on your practice’s size and profitability and on your personal goals. Practices in the roughly $1–$1.5 million revenue range often fit a doctor-to-doctor sale well. Larger practices can point more clearly toward the DSO path. Owners in the $1.5–$3 million revenue range can often pursue either path successfully. Because McLerran works both markets in roughly equal measure, the firm runs a side-by-side valuation that quantifies your worth in both markets before recommending a direction. That comparison, rather than a broker’s preference for one lane, can be one of the main factors guiding the decision.
How do I evaluate whether a DSO’s rollover equity is worth taking?
Rollover equity can be evaluated like any investment. Helpful questions include whether the DSO’s overall platform is profitable and whether revenue is still growing at the offices it already owns. The experience and stability of the management team also matter. The track record of the private equity firm backing the platform, including whether it has successfully exited similar investments before, can provide additional context. Terms such as vesting schedule, liquidation preferences, drag-along provisions, and transfer restrictions on the equity should be reviewed carefully. McLerran helps owners work through these questions systematically, models the equity’s potential value under conservative and more optimistic recap assumptions, and steers clients away from undercapitalized platforms where the equity may carry a meaningful risk of write-down or prolonged illiquidity.
Conclusion: Control the Narrative and Protect Your Legacy
Selling a dental practice to private equity can be viewed as a four-part journey: understand your options, create competition, find the right fit, and maximize your outcome. Each step benefits from preparation, process, and an advocate who works exclusively on your behalf.
McLerran & Associates has evaluated more than 10,000 dental practices and closed approximately 2,000 transactions totaling roughly $2 billion in volume. The firm does not simply list practices and hope for the best. It builds diligence-grade valuations, runs structured auction processes, negotiates every term of the LOI, and defends the agreed value through close.
The biggest financial decision of your career can merit the same level of representation the buyer brings to the table every week. Discuss your practice and transition goals with McLerran & Associates in a confidential discovery call and explore the path that fits your practice and your legacy.
